Octagon Capital Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Octagon Capital Advisors’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,278,000	Closed	-$27.4M	–	44
2022 Q4	$27.4M	Buy	+1,278,000	New	+$27.3M	4.26%	7
2021 Q4	–	Sell	-277,057	Closed	-$4.5M	–	36
2021 Q3	$4.5M	Sell	277,057 -402,979	-59%	-$4.39M	1.11%	21
2021 Q2	$4.29M	Hold	680,036	–	–	0.89%	28
2021 Q1	$4.2M	Hold	680,036	–	–	1.58%	22
2020 Q4	$4.7M	Buy	+680,036	New	+$4.35M	1.63%	21

Octagon Capital Advisors's ISEE Position: Q1 2023 in Review

Octagon Capital Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2023, closing a stake of 1,278,000 shares — an estimated $27.4M sold.

Octagon Capital Advisors first reported a position in ISEE in Q4 2020 and held it in 5 quarters. The position peaked at $27.4M in Q4 2022. 223 funds tracked by Wall St. Rank hold ISEE as of Q1 2023.

Octagon Capital Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Octagon Capital Advisors sold 1,278,000 IVERIC bio, Inc. Common Stock shares in Q1 2023, an estimated $27.4M.
Octagon Capital Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Octagon Capital Advisors's IVERIC bio, Inc. Common Stock position peaked at $27.4M in Q4 2022.
223 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2023.

Based on Octagon Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.